

Pharmion

[View the current Pharmion Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/8302-Pharmion.html)

(<http://www.bioportfolio.com/biocorporate/8302-Pharmion.html>)

Contact Details:

2525 28th St., Suite 200

Boulder

CO

80301

United States of America

Tel: +1 720 564 9100

Fax: +1 720 564 9191

Email: IR@Pharmion.com

Pharmion is a global specialty pharmaceutical company that is dedicated to the hematology and oncology communities. With proven development and regulatory professionals and an experienced global commercialization team, we concentrate our resources on acquiring, developing, and commercializing innovative products.

We work in partnership with a network of scientific and clinical advisors to identify and develop these products for global markets. To expand each product's potential, we have established our own commercial organizations in the United States, Europe, and Australia and have created distribution partnerships in 30 additional countries. With this international network we can reach physicians and their patients in more than 40 countries.

Through these efforts, we seek to provide greater therapeutic options to hematologists and oncologists with the ultimate goal of extending survival and improving patients' quality of life.

Recent Publications by Pharmion:



- [Epigenetic alterations and cancer: new targets for therapy.](#)

*Over the last two decades, preclinical and clinical research has...*6th December, 2007
Pharmion Corp, 1700 Owens Street, Suite 205, San Francisco, CA 94158, USA.- IDrugs. 2007
Oct;10(10):709-12.

- [Future directions in haematology: beyond multiple myeloma.](#)

*Thalidomide acts on the microenvironment of myelodysplastic syndromes...*14th October, 2005
Pharmion- Acta Haematol. 2005;114 Suppl 1:27-32. ([DOI Direct Link](#))

- [EntreMed Reports Clinical Program Progress and Company Update](#)
Forbes.com: Nov 12 2008 12:50PM Matching: pharmion
- [EntreMed Reports Clinical Program Progress and Company Update](#)
San Antonio Business Journal: Nov 12 2008 12:44PM Matching: pharmion
- [EntreMed Reports Clinical Program Progress and Company Update](#)
Biz Journals: Nov 12 2008 12:26PM Matching: pharmion
- [EntreMed Reports Clinical Program Progress and Company Update](#)
Street Insider: Nov 12 2008 12:23PM Matching: pharmion
- [EntreMed Reports Clinical Program Progress and Company Update](#)
Calibre Macro World: Nov 12 2008 12:11PM Matching: pharmion
- [EntreMed Reports Third Quarter 2008 Financial Results](#)
Portland Business Journal: Nov 6 2008 12:45PM Matching: pharmion
- [EntreMed Reports Third Quarter 2008 Financial Results](#)
Calibre Macro World: Nov 6 2008 12:03PM Matching: pharmion
- [Celgene Reports Record Third Quarter 2008 Product Sales and Operating Profits](#)
Pharmacy Choice: Nov 1 2008 4:57AM Matching: pharmion
- [MethylGene reacquires rights to cancer drug from Celgene](#)
Pharmaceutical Business Review: Oct 31 2008 8:16AM Matching: pharmion
- [MethylGene Shares Tumble After Breakup with Celgene](#)
Pharmacy Choice: Oct 29 2008 9:35AM Matching: pharmion
- [MethylGene Shares Tumble After Breakup with Celgene](#)
Therapeutics Daily: Oct 28 2008 7:45PM Matching: pharmion
- [Methylgene Reacquires Rights To MGCD0103 From Celgene And Implements Strategic Plan To Focus On Development Of](#)
Pharma Live: Oct 28 2008 11:34PM Matching: pharmion
- [MethylGene Reacquires Rights to MGCD0103 From Celgene and Implements Strategic Plan to Focus on Development of](#)
Pharmacy Choice: Oct 28 2008 10:11AM Matching: pharmion
- [Lutonix Inc. Announces \\$20 Million Series B Financing](#)
Montana's News Station: Oct 27 2008 11:57PM Matching: pharmion
- [Lutonix Inc. Announces \\$20 Million Series B Financing](#)
KSLA: Oct 27 2008 6:32PM Matching: pharmion

Pharmion Patents:



- 7192781- [Methods for stabilizing 5-azacytidine in plasma](#)
- 7078518- [Forms of 5-Azacytidine](#)
- 7038038- [Synthesis of 5-azacytidine](#)
- 6943249- [Methods for isolating crystalline Form I of 5-azacytidine](#)

- 6887855- [Forms of 5-azacytidine](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

